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OBJECTIVES We sought to explore the relationship between a Tcap gene (TCAP) abnormality and
cardiomyopathy.
BACKGROUND Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) cause severe
heart failure and sudden death. Recent genetic investigations have revealed that mutations of
genes encoding Z-disc components, including titin and muscle LIM protein (MLP), are the
primary cause of both HCM and DCM. The Z-disc plays a role in establishing the
mechanical coupling of sarcomeric contraction and stretching, with the titin/Tcap/MLP
complex serving as a mechanical stretch sensor. Tcap interacts with the calsarcin, which
tethers the calcineurin to the Z-disc.
METHODS The TCAP was analyzed in 346 patients with HCM (236 familial and 110 sporadic cases) and
136 patients with DCM (34 familial and 102 sporadic cases). Two different in vitro
qualitative assays—yeast two-hybrid and glutathion S-transferase pull-down competition—
were performed in order to investigate functional changes in Tcap’s interaction with MLP,
titin, and calsarcin-1 caused by the identified mutations and a reported DCM-associated
mutation, R87Q.
RESULTS Two TCAP mutations, T137I and R153H, were found in patients with HCM, and another
TCAP mutation, E132Q, was identified in a patient with DCM. It was demonstrated by the
qualitative assays that the HCM-associated mutations augment the ability of Tcap to interact
with titin and calsarcin-1, whereas the DCM-associated mutations impair the interaction of
Tcap with MLP, titin, and calsarcin-1.
CONCLUSIONS These observations suggest that the difference in clinical phenotype (HCM or DCM) may be
correlated with the property of altered binding among the Z-disc components. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.08.058Cardiol 2004;44:2192–201) © 2004 by the American College of Cardiology Foundation
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tardiomyopathy is one of the major causes of sudden death
nd/or progressive heart failure, and cases of cardiomyopa-
hy are mainly classified into hypertrophic cardiomyopathy
HCM) and dilated cardiomyopathy (DCM). Hypertrophic
ardiomyopathy is characterized by left ventricular (LV)
ypertrophy accompanied by myofibrillar disarray and man-
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ccepted August 25, 2004.fests as diastolic dysfunction of the cardiac ventricles,
hereas DCM is characterized by a dilated ventricular
avity with systolic dysfunction (1). Recent genetic investi-
ations have revealed that HCM is caused by mutations in
he genes for sarcomeric proteins, such as MYH7 (cardiac
eta-myosin heavy chain), TNNT2 (cardiac troponin T),
nd ACTC (cardiac alpha-actin) (2). Mutations in the
arcomere genes also cause DCM (3,4). In addition, muta-
ions in the genes for Z-disc or costameric proteins, such as
MD (dystrophin), DES (desmin), and SGCD (-
arcoglycan), cause DCM (5–7).
The Z-disc plays various roles in sarcomeric organization,
orce transduction, and force transmission (8). Because the
-disc is important in establishing the mechanical coupling
f the sarcomere, defects in the Z-disc proteins may lead to
ither HCM or DCM. Titin, also known as connectin, is a
omponent of the sarcomere and contains distinct motifs
hat sequentially unfold as the muscle is stretched (9). Titin
orms a complex with alpha-actinin and alpha-actin at the
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December 7, 2004:2192–201 TCAP Mutation in Cardiomyopathy-disc (Fig. 1) (10,11). We previously reported on two
TN (titin) mutations at the actinin-interaction domain,
hich increases and decreases the ability of titin to interact
ith alpha-actinin: an HCM-associated mutation that in-
reases the ability of titin to interact with alpha-actinin and
DCM-associated mutation that decreases it (12,13). Titin
lso interacts with another Z-disc component, titin-cap
Tcap/telethonin) (14,15), and we found another DCM-
ssociated TTN mutation at the Tcap-interaction domain,
hich impaired the interaction with Tcap (13). In addition,
ther DCM-associated TTN mutations not located in the
-disc region have been reported (13,16), although the
unctional changes caused by these mutations remain
nknown.
Tcap is a 19-kd protein required for sarcomerogenesis in
triated muscles (14). It is phosphorylated by titin kinase at
er157 and is suggested to play a key role in sarcomere
ssembly (17). Tcap interacts with calsarcin and minK at the
-terminal half and the C-terminal regions, respectively
18,19). Tcap also interacts with muscle LIM protein
MLP), and a DCM-associated MLP mutation abolishes
he interaction (20). In addition, another DCM-associated
LP mutation was reported to impair the interaction of
cap with alpha-actinin-2, whereas a DCM-associated
lpha-actinin-2 mutation impaired its interaction with
LP (21). On the other hand, four MLP mutations were
Abbreviations and Acronyms
CS-1  calsarcin-1
DCM  dilated cardiomyopathy
GST  glutathion S-transferase
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
MLP  muscle LIM protein
PCR  polymerase chain reaction
RT  reverse transcription
SSCP  single-strand conformation polymorphism
Thio  thioredoxin
WT  wild-type
Y2H  yeast two-hybrid
igure 1. Schematic representation of Z-disc proteins. The Z-disc pro-
eins mentioned in the text and their interactions are schematically shown.P
S-1  calsarcin-1; MLP  muscle LIM protein; PKC  protein kinase
; ZASP  Z-band alternatively spliced PDZ-motif protein.eported in HCM, one of which was shown to decrease the
inding to alpha-actinin (22).
To further explore the relationship between an abnormal-
ty in Z-disc proteins and cardiomyopathy, we searched for
utations in the Tcap gene (TCAP) in a cohort of patients
ith HCM and DCM. Two HCM-associated TCAP
utations and a novel DCM-associated TCAP mutation
ere identified in this study. We investigated the interac-
ion of Z-disc components titin, MLP, and calsarcin-1
CS-1) with Tcap in the presence of the TCAP mutations.
e report here that the HCM-associated and DCM-
ssociated mutations showed different changes in Tcap’s
nteraction properties with these Z-disc components.
ETHODS
ubjects. A total of 346 and 136 genetically unrelated
atients with HCM and DCM, respectively, were chosen as
ubjects. Among them, 332 HCM and 135 DCM patients
ere Japanese, and 14 HCM patients and 1 DCM patient
ere Korean. A family history of the disease (i.e., at least
ne blood relative with the same disease and/or unexplained
udden cardiac death 45 years of age) was observed in 236
atients with HCM and 34 with DCM. The patients with
CM were diagnosed based on medical history, physical
xamination, electrocardiogram, and echocardiogram (LV
all thickness 14 mm), whereas patients with DCM were
iagnosed based on a medical history, physical examination,
lectrocardiogram, and echocardiogram (impaired LV func-
ion and fractional shortening 25%), in the absence of
oronary artery disease, as evaluated by coronary angiogra-
hy (12,13,23). When a patient was found to have a TCAP
utation, blood relatives were examined for the mutation, if
vailable. Control subjects consisting of 240 Japanese and 70
orean healthy individuals were tested for the mutations
dentified in this study. Blood samples were obtained from
ach subject after obtaining informed consent. The study
rotocol was approved by the Ethics Reviewing Committee
f Medical Research Institute, Tokyo Medical and Dental
niversity, and Institutional Reviewing Board of the Sam-
ung Medical Center.
nalysis of known disease genes for HCM and DCM. Pa-
ients with HCM were screened for mutations in MYH7,
NNT2, MYBPC3 (cardiac myosin-binding protein C),
NNI3 (cardiac troponin I), MYL2 (myosin regulatory light
hain), MYL3 (myosin essential light chain), TPM1 (alpha-
ropomyosin), TTN, MLP, and ACTC, whereas patients
ith DCM were analyzed for mutations in ACTC, DES,
MD, LMNA (lamin A/C), TTN, MYH7, TNNT2,
YBPC3, and TNNI3, by using the polymerase chain
eaction (PCR) single-strand conformation polymorphism
SSCP) method (24–26), and the mutations were con-
rmed by sequencing the PCR products. The SSCP
ethod we employed usually detects a point mutation with
n efficacy of about 90% (25,26). The conditions of the
CR and primers used in the analyses are available on
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TCAP Mutation in Cardiomyopathy December 7, 2004:2192–201equest. The screening analysis revealed 36 MYH7, 24
YBPC3, 20 TTNT2, 6 TNNI3, 2 MYL2, 1 TPM1, 1
TN, and 2 MYL3 mutations in 91 familial HCM cases,
nd 5 MYBPC3, 3 TNNT2, 3 TNNI3, 1 MYL3, 1 TTN,
nd 2 MYH7 mutations in 15 sporadic HCM cases. In
ddition, we found 1 DES and 3 TTN mutations in four
amilial DCM cases and 1 TTN and 3 DMD mutations in
our sporadic DCM cases (details will be reported
lsewhere).
utational analysis of TCAP. The primers used in this
tudy are listed in Table 1. Both TCAP-1F and -1R for
xon 1 and TCAP-2F and -2R for exon 2 were used in the
nalysis of TCAP. The PCR products from the patients
ere sequenced from the primers on both strands. Controls
ere analyzed only for exon 2.
nalysis of the cardiac myosin-binding protein C gene
MYBPC3) in a Korean family. Exon 6 of MYBPC3 was
mplified by PCR with MYBPC3-Ex6F and -Ex6R. The
CR products showed an abnormal SSCP pattern in
atients with HCM, and the sequencing analysis demon-
trated that this was due to an A-to-G change in codon 236.
his change destroyed an AluI site. In order to detect the
utation in the blood relatives, the PCR products were
igested by AluI and electrophoresed in 2.0% agarose gel.
east two-hybrid (Y2H) assay. A human TCAP comple-
entary deoxyribonucleic acid (cDNA) fragment (nucleo-
ides 11–514; GenBank AJ000491, corresponding to amino
cids 1–167) was amplified from cDNA generated from
otal cardiac RNA by the reverse transcription (RT)-PCR
ethod using primers TCAP-EcoF and -BamR.
able 1. Nucleotide Sequence of Primers Used in This Study
Name
CAP-1F GCTATTTAAAGG
CAP-1R CAGGGACTCTA
CAP-2 AGAGAGCAACA
CAP-2R GCGGGCACAGC
YBPC3-Ex6F TAAGGGTGCGG
YBPC3-Ex6R GGGAGCCCGAG
CAP-EcoF GAATTCATGGC
CAP-BamR GGATCCTCAGC
CAP-87MR CGGCAGTACCT
CAP-87MF CAGCTGCCCTA
CAP-132MF ACCGCCAGCAG
CAP-132MR CAGCCACCTGC
CAP-137MF GTGGCTGAGAT
CAP-137MR GGGCAGCTGCT
CAP-153MR GGACAGGGAGC
CAP-153MF CCCGGTGCCCT
LP-EcoF GAATTCATGCC
LP-BamR GGATCCTCATTC
S-1-EcoF GAATTCATGCTA
S-1-BamR GGATCCATCTG
TN-NcoIF CCATGGTGACA
TN-BamR GGATCCAGGTA
cap-XhoT7R ACCCATTTGCTG
cap-120XhoR CTCGAGCTCCA
LP-Xho1R CTCGAGTTCTTTardiomyopathy-associated mutations were introduced gnto the cDNA fragment by the primer-mediated mutagen-
sis method, as described previously (13). The following
rimers were used: R87Q: TCAP-EcoF, -87MR, -87MF,
nd -BamR; E132Q: TCAP-EcoF, -132MF, -132MR,
nd -BamR; T137I: TCAP-EcoF, -137MF, -137MR, and
Bam; R153H: TCAP-EcoF, -153MR, -153MF, and
Bam. Both S157A and S157D were constructed from
DNA clones obtained from Dr. S. Labeit (15). The PCR
ragments were cloned into pCRII (Invitrogen, Carlsbad,
alifornia) for sequence confirmation. In order to obtain
ait plasmids, normal and mutant TCAP cDNA fragments
ere cleaved by digestion with EcoRI and BamHI, gel-
urified, and inserted into pGBKT7 (Clontech, Palo Alto,
alifornia). A human MLP cDNA fragment (nucleotides
8–642; GenBank U49837, corresponding amino acids
–194) and a CS-1 cDNA fragment (nucleotides 86–424;
enBank BC005195, corresponding amino acids 1–113)
ere also obtained by the RT-PCR method with primers
LP-EcoF and -BamR, and CS-1-EcoF and -BamR,
espectively. A human titin Z1-Z2 cDNA fragment (nucle-
tides 123–731; GenBank NM-003319, corresponding
mino acids 1–203) was obtained by the RT-PCR method
ith primers TTN-NcoIF and -BamR. The MLP, the
1-Z2 region of titin, and CS-1 cDNA fragments were
loned into pGADT7 (Clontech), and the nucleotide se-
uences were confirmed. The TCAP constructs and either
LP, titin, or CS-1 constructs were used for co-
ransformation of Saccharomyces cerevisae (strain Y187) on
gar plates lacking leucine and tryptophan. Several indepen-
ent transformants (n  8 to 10) were tested for beta-
Sequence (5= to 3=)
CTGGGA
GACC
CCCAG
GCC
CTTGT
AGGACA
CTCAGAGCTG
TCTGTGCTTCCTG
GGCAGGG
GCAGGTA
GCTG
CGGT
AAAGCAG
TGATCTC
GAAGGGC
TCGCTCC
TGGGGCGGAGGCGCAA
CTTTTCCACTTGTTGTGTAAGGCC
CATAATACTATG
TGTTGGGAGGAGTCAA
CAAGCACCGAC
CTTCTTCACCTTGA
ACCAGTCATGCTAGCCATCTCGAGGCCTCTCTGTGCTTC
CCAGCAGCTCCTG
TTCCACTTGTTGTGTAAGGCCGC
GCA
GCT
GGA
AGC
CCC
TAC
CTC
GCT
CCA
GTG
TGG
CAT
TTA
GAT
TCA
AAAC
TTT
TCA
GGG
ACT
CTT
TCC
GCGalactosidase activity, as described previously (12,13).
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December 7, 2004:2192–201 TCAP Mutation in Cardiomyopathyransformants carrying either bait plasmids or activator
lasmids did not show any significant beta-galactosidase
ctivity, demonstrating no self-activation. The data are
resented as the mean value  SD. The Student t test was
sed to estimate statistical significance.
lutathion S-transferase (GST) pull-down competition
ssay. Each cDNA fragment used in the GST pull-down
ompetition assay was generated by the PCR from each
2H construct as a template, using combinations of the
ollowing primers: full Tcap fragment: Tcap-EcoF and
XhoT7R; short Tcap fragment: Tcap-EcoF and -120XhoR;
itin Z1-Z2 fragment: TTN-NcoIF and -BamR; MLP:
LP-EcoF and -Xho1R; CS-1: CS-1-EcoF and -BamR.
he TCAP fragments were cloned into pBAD/Thio-TOPO
Invitrogen) encoding the C-terminal polyhistidine tag to
btain a thioredoxin (Thio), T7, and His-tag fusion constructs.
he titin, MLP, and CS-1 fragments were cloned into
GEX5X-1 (Amersham, Piscataway, New Jersey) to obtain
ST-fusion constructs. All constructs were sequenced to
nsure that no PCR errors were introduced. The GST-fusion
onstructs were used for the transformation of BL21-Gold
Stratagene, La Jolla, California). The transformants were
ollected in PBS with 1% Triton X-100 and sonicated. The
ST-fusion proteins were purified and fixed on glutathione-
epharose beads as per the manufacturer’s instructions. Thio-
usion TCAP constructs were introduced into TOP10 (Invitro-
en). Thio-fusion proteins were prepared under the denaturing
ondition (6-M urea) and purified by binding with Ni2-
harged resi, as per the manufacturer’s instructions. A GST-
nly construct was used as a negative control. Binding assays
ere performed as described in the literature (14). Briefly, 5
l each of Thio-fusion full Tcap protein and short Tcap
rotein (each 0.5 g/l) were added to 5 l of either
ST-fusion titin, MLP, or CS-1 (each 0.5 g/l) in 100 l
f binding buffer (20 mmol/l Tris, 50 mmol/l NaCl, pH
.0). The ratio of Thio-fusion proteins to each GST-fusion
rotein used in the assay was determined in preliminary
xperiments, in which fixed amounts of Thio-fusion pro-
eins were mixed with various amounts of GST-fusion
roteins. The mixture was incubated for 1 h at 4°C, washed
hree times with 400 l of binding buffer, suspended in
odium dodecyl sulfate (SDS) sample buffer, separated by
DS-polyacrylamide gel electrophoresis (PAGE) in 10%
olyacrylamide gels, and transferred to duplicated nitrocel-
ulose membranes. The membranes were blocked with 3%
onfat dry milk, incubated overnight at 4°C with anti-T7
ag monoclonal antibody (Novagen, San Diego, California)
1:7500) or goat anti-GST antibody (Amersham) (1:1000)
s the first antibody. After washing with Tris-buffered saline
50 mmol/l Tris, 150 mmol/l NaCl, pH 7.5) containing
.05% Tween 20, the membranes were incubated with
nti-mouse immunoglobulin G conjugated with alkaline
hosphatase (AP) (Promega, Madison, Wisconsin) (1:
500) or anti-goat immunoglobulin G conjugated with AP
Chemicon, Temecula, California) (1:7500), respectively, as
he second antibody for 1 h at room temperature, and the (mmunocomplex was stained by using an Alkaline Phos-
hatase Conjugate Substrate Kit (Bio-Rad, Hercules, Cal-
fornia). To confirm the specificity of the assay, we used
ffinity-purified rabbit polyclonal anti-Tcap antibody
kindly provided by Dr. S. Labeit) as the first antibody,
ubstituting for anti-T7 antibody, and obtained similar
esults. The experiments were repeated at least five times,
nd each blot was analyzed by National Institutes of Health
maging in order to measure the contents of wild-type (WT)
r mutant full Tcap protein in relation to that of WT short
cap. The data are represented as the mean value  SD. The
tudent t test was used to estimate statistical significance.
ESULTS
dentification of TCAP mutations in HCM. TCAP was
nalyzed by direct sequencing in a cohort of patients with
CM. There were three variations not accompanied by
mino acid replacement: a CAC-to-CAT change in codon
2, a GGC-to-GGA change in codon 75, and a GCC-to-
CA change in codon 151. They were found in both
atients and healthy controls at a similar frequency (variant
llele frequencies in the patients and controls were 0.004
nd 0.003, 0.003 and 0.003, and 0.432 and 0.440, respec-
ively), indicating that these variations are polymorphisms
ot associated with the disease. In contrast, two missense
utations—a C-to-T transition in codon 137 replacing
CA (Thr) with ATA (Ile) (T137I) and a G-to-A transi-
ion in codon 153 replacing CGT (Arg) with CAT (His)
R153H)—were found in Japanese patients. The clinical
haracteristics of the patients and their blood relatives
arrying these mutations are shown in Table 2.
A T137I mutation was found in a female patient (JH945
I-2) (Figs. 2a and 2b) and her son, both affected with
CM (JH945 III-1) (Table 2). On the other hand, an
153H mutation was found in a male patient (JH14 II-1)
Figs. 2c and 2d) and his sister (JH14 II-3) (Fig. 2c), both
ith HCM; this mutation was inherited by his sons, who
id not suffer from HCM at the time of the examination
JH14 III-1 and III-2, respectively) (Table 2). These
issense mutations were not found in unrelated controls. In
ddition, the patient cohort was screened for mutations in
he known disease genes for HCM, and the patients
arrying the TCAP mutations did not show any mutations
n the known disease genes.
dentification of a novel TCAP mutation in DCM. While
nalyzing a cohort of DCM patients, we found a novel
CAP mutation in a Korean patient with DCM (SM728
I-5) (Fig. 3a). The patient had suffered from heart failure
t the age of 34 years (Table 2) and undergone heart
ransplantation at the age of 35 years. The analysis demon-
trated a missense mutation in codon 132, a replacement of
AG (Glu) with CAG (Gln) (E132Q) (Fig. 3b). This
utation was not found in the controls. A family study
evealed that his mother (SM728 I-3) and maternal uncle
SM728 I-4) were affected by HCM, but no TCAP muta-
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TCAP Mutation in Cardiomyopathy December 7, 2004:2192–201ion was found in either of them (Fig. 3a). Instead, the
CAP mutation was transmitted from the father (SM728
-2) to his son (SM728 III-4), who did not manifest a
CM phenotype at the time of the examination (Fig. 3a)
Table 2).
We searched for mutations in the known HCM-causing
enes in his mother, and a missense mutation of MYBPC3,
236G, which is a replacement in codon 236 of AGC (Ser)
ith GGC (Gly), was identified (Fig. 3c). This mutation
as also found in the affected uncle (Fig. 3a) and in another
nrelated Japanese patient (data not shown), but not in the
ontrols, suggesting that it may be a disease-causing muta-
ion. As shown in Figure 3a, the MYBPC3 mutation was
ot inherited by the proband, but was found in his brother
SM728 II-3) and his brother’s offspring (SM728 III-1 and
II-2), none of whom had HCM at the time of the
xamination (Table 2). Because both mother and uncle
eveloped HCM after the age of 50 years, it is possible that
he MYBPC3 mutation is associated with late-onset HCM
2). These data demonstrate that this family has two
ifferent gene mutations: one is the TCAP mutation asso-
iated with DCM and the other is the MYBPC3 mutation
ssociated with HCM. In addition, the DCM cohort was
able 2. Clinical Characteristics of Individuals Carrying the TCA
ID Mutation
Age (yrs),
Gender
NYHA
Class
LVEDD
(mm)
L
H945 TCAP 62, F I 44
I-2 T1371
H945 TCAP 29, M I 43
II-1 T1371
H14 TCAP 48, M I 42
I-1 R153H
H14 TCAP 67, F I 38
I-2 R153H
H14 TCAP 21, M I 46
II-1 R153H
H14 TCAP 19, M I 46
II-2 R153H
M728 TCAP 63, M I 53
-2 E132Q
M728 TCAP 34, M III 55
I-5 E132Q
M728 TCAP 5, F I 32
II-4 E132Q
M728 MYBPC3 64, F I 55
-3 S256G
M728 MYBPC3 60, M I 55
-4 S256G
M728 MYBPC3 39, M I 52
I-3 S256G
M728 MYBPC3 12, F I 37
II-1 S256G
M728 MYBPC3 10, M I 37
II-2 S256G
or ID, see Figures 1 and 2. Age represents age at examination.
ECG  electrocardiographic; F  female; FS  fractional shortening; I-AV  fir
VEDD left ventricular end-diastolic diameter; LVESD left ventricular end-sys
ssociation; PWTmax  maximum posterior wall thickness; RVH  right ventriculcreened for mutations in the known disease genes for tCM, and the patient carrying the TCAP mutation did not
ave any mutations in the known disease genes thus far
ested.
As shown in Figure 4, the TCAP mutations identified in
his study were found in the evolutionary conserved residues
except for E132Q, but this position is occupied by an acidic
esidue in the rat and mouse) at or near the binding domains
o titin (14), MLP (20), and calsarcin-1 (19).
lterations in the interaction of Tcap with MLP, titin
nd CS-1 caused by TCAP mutations, as found in the
2H assay. In order to investigate the functional conse-
uences of TCAP mutations for Tcap’s interaction with
LP, titin, and CS-1, we performed Y2H assays. Wild-
ype and mutant Tcap’s were constructed in an activator
lasmid and co-transformed with a bait plasmid containing
DNA for MLP, titin (Z1-Z2 domains), or CS-1. Because
he R153H mutation was found near the phosphorylation
ite, Ser157, and because this site is important in Tcap’s
nteraction with minK (18), we investigated two other
onstructs, S157A (a model of the unphosphorylated form)
nd S157D (a model of the phosphorylated form).
We measured beta-galactosidase activity in several inde-
endent transformants in order to investigate qualitatively
MYBPC3 Mutation
IVSmax
(mm)
PWTmax
(mm) FS (%) ECG Findings
17 11 39 WPW syndrome, LVH
16 8 35 LVH, abnormal Q-wave
23 12 29 Abnormal Q-wave
17 13 26 LVH
10 9 41 Normal
10 10 39 Normal
11 11 43 Normal
10 9 9 RVH, I-AV block
4 6 34 Normal
21 9 51 LVH, T-wave abnormality
27 11 44 Inverted T-wave in V5–V6
12 10 44 Normal
9 7 38 Normal
7 7 38 Normal
ree atrioventricular block; IVSmax  maximum intraventricular septal wall thickness;
ameter; LVH left ventricular hypertrophy; Mmale; NYHA New York Heart
ertrophy.P or
VESD
(mm)
27
28
30
28
27
28
30
50
21
27
31
29
23
23
st-deg
tolic di
ar hyphe strength of protein-protein interaction (Table 3). It was
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December 7, 2004:2192–201 TCAP Mutation in Cardiomyopathyemonstrated that the DCM-associated mutations, R87Q
nd E132Q, significantly impaired the interaction (both
ere p  0.01). On the other hand, the HCM-associated
utations, T137I and R153H, showed no statistical differ-
nce (p  0.29 and 0.54, respectively). The unphosphory-
ated Tcap model (S157A) and the phosphorylated model
S157D) showed virtually no change (p  0.49 and 0.70,
espectively).
We next investigated Tcap’s interaction with titin. The
CM-associated Tcap mutations showed statistically sig-
igure 3. Mutational analyses of TCAP and MYBPC3 in a Korean family.
a) Pedigree of a Korean family with dilated cardiomyopathy (DCM) and
ypertrophic cardiomyopathy (HCM). Right-half-filled and left-half-
lled symbols indicate DCM and HCM, respectively. Plus symbols to the
ight and left of individual IDs represent TCAP (E132Q) and MYBPC3
S236G) mutations, respectively. A TCAP mutation was found in I-2, II-5,
nd III-4, whereas an MYBPC3 mutation was found in I-3, I-4, II-3, III-1,
nd III-2. Open symbols represent individuals without cardiac disease
henotypes. SCD sudden cardiac death (II-4: suffered from heart failure
nd died suddenly at the age of 26 years). (b) Direct sequencing data of
CAP exon 2 from a control and the proband (SM728 II-5). Codon 132
f the control was GAG (Glu), whereas that of SM728 was heterozygous
or a CAG mutation (Gln). (c) Direct sequencing data of MYBPC3 exon
from the mother of the proband (SM728 I-3). Codon 236 of the control
as AGC (Ser), whereas that of the mother was heterozygous for a GGC
utation (Gly).igure 2. Mutational analysis of TCAP in hypertrophic cardiomyopathy
HCM). Filled and open symbols indicate affected and unaffected
ndividuals, respectively. The presence () or absence () of a TCAP
utation is noted. SCD  sudden cardiac death (JH14: II-4 and II-5 died
fter exercise at age 44 and 33 years, respectively; JH945: I-1 died after
xercise at age 34 years). (a) Pedigree of a Japanese HCM family. The
rrow indicates the proband (JH945 II-2). A TCAP mutation was found in
I-2 and III-1. (b) Direct sequencing data of TCAP exon 2 from a control
left) and the proband (right). Codon 137 of the control was ACA (Thr),
hereas the patient was heterozygous for an ATA mutation (Ile). (c)
edigree of another Japanese HCM family. A TCAP mutation was found
n II-1, II-3, III-1, and III-2. (d) Direct sequencing data of TCAP exon 2
rom a control and the proband (JH14 II-1). Codon 153 of the control was
GT (Arg), whereas the patient was heterozygous for a CAT mutationificant impairment (both were p  0.001). In clear
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TCAP Mutation in Cardiomyopathy December 7, 2004:2192–201ontrast, the HCM-associated mutations significantly aug-
ented the interaction (both were p 0.001). On the other
and, the unphosphorylated model and phosphorylated
odel showed no change in the interaction (p  0.48 and
 0.15, respectively).
Because calsarcin-3, a skeletal muscle-specific calsarcin,
as reported to interact with Tcap, and cardiac muscle
xpresses another calsarcin, CS-1 (19), we examined the
nteraction between Tcap and CS-1. Co-transformants of
cap and CS-1 constructs showed that the beta-
alactosidase activity of WT Tcap colonies was 1.04  0.03
nits, whereas no beta-galactosidase activity was observed in
olonies carrying either Tcap or CS-1. These data suggest
hat CS-1 could interact with Tcap. The DCM-associated
utations significantly impaired the interaction (both were
 0.001). The HCM-associated mutations, in clear
ontrast, augmented the interaction (both were p  0.001).
nphosphorylated or phosphorylated Tcap models showed
o change (p  0.58 and p  0.19, respectively).
These observations demonstrate that the DCM-
ssociated mutations impair the interaction of Tcap not only
ith MLP but also with titin and CS-1. On the other hand,
he HCM-associated mutations augment Tcap’s interaction
ith titin and CS-1 without significant changes in the
nteraction with MLP. In addition, the phosphorylation
tatus of Tcap does not affect its interaction with these
-disc components.
able 3. Relative Binding of Wild-Type and Mutant Tcap to
LP, Titin, and CS-1, as Assessed by the Y2H Assays
MLP Titin CS-1
T 1.0* 1.0* 1.0*
87Q 0.35 0.07† 0.31 0.04‡ 0.76 0.09‡
132Q 0.67 0.11† 0.41  0.03‡ 0.63 0.04‡
137I 1.11 0.17 1.57  0.12‡ 1.27 0.11‡
153H 1.11 0.26 1.28  0.12‡ 1.25 0.04‡
157A 0.94 0.25 0.98  0.07 0.97 0.18
157D 1.10 0.34 0.94  0.11 0.96 0.08
Relative beta-galactosidase activity in wild-type (WT) Tcap colonies was defined as
.0. The beta-galactosidase activities (arbitrary unit) for WT Tcap with MLP, titin,
nd CS-1 were 0.42  0.08, 8.88  0.35, and 1.04  0.03, respectively. †p  0.01.
igure 4. Alignment of Tcap amino acid sequences. The amino acid
equence of human Tcap was aligned with that of bovine, rat, and mouse
caps. The mutations found in patients with hypertrophic cardiomyopathy
HCM) and dilated cardiomyopathy (DCM) are represented along with
he phosphorylation site, Ser157, indicated by an arrowhead. Dashes
ndicate identity to human Tcap.M
p  0.001. Data are presented as the mean value  SD.
CS-1  calsarcin-1; MLP  muscle LIM protein.ST pull-down competition assay of the interaction
etween Tcap and the other Z-disc components, MLP,
itin, and CS-1. In order to investigate the altered inter-
ction between Tcap and the other Z-disc components by
n independent method, we performed GST pull-down
ompetition assays. The MLP, titin, and CS-1 proteins
ere expressed as GST-fusion proteins. The WT and
utant Tcap proteins were expressed as Thio-fusion pro-
eins. These recombinant Tcap proteins were designated as
est-Tcap-WT or test-Tcap-mutant (e.g., test-Tcap-
87Q). A short form of Tcap (amino acids 1–120) protein
as also constructed as a Thio-fusion protein, to be used as
competitor (designated as comp-Tcap). Equal amounts of
est-Tcap and comp-Tcap (Fig. 5a) were complexed with
ach GST-fusion protein. After incubation and washing,
he Tcap proteins were eluted from the complex, separated
y SDS-PAGE, and immunoblotted with anti-GST anti-
ody and anti-T7 antibody so that the amounts of GST-
usion proteins complexed with the test-Tcap in the pres-
nce of comp-Tcap could be measured. Test-Tcap-WT did
ot form a complex with GST-only proteins (data not
hown).
As shown in Figure 5b, the interaction between GST-
LP and test-Tcap-R87Q was weak, compared with that
etween GST-MLP and test-Tcap-WT. Similarly, the
nteraction between GST-MLP and test-Tcap-E132Q was
eak. In contrast, the interactions between the GST-MLP
nd HCM-associated mutant Tcap, test-Tcap-T137I or
R153H, were comparable with that with test-Tcap-WT.
either S157A nor S157D showed remarkable changes.
he results obtained with GST-titin (Fig. 5c) and GST-
S1 (Fig. 5d) demonstrated that the DCM-associated
utations impaired the interaction with titin and CS-1,
espectively. On the other hand, the HCM-associated
utations showed an augmented interaction with titin and
S1 (Figs. 5c and 5d, respectively).
The assays were repeated and each blot was analyzed by
ational Institutes of Health imaging to measure semi-
uantitatively the intensity of each test-Tcap in comparison
ith that of comp-Tcap. The altered interaction between
cap and the Z-disc components, as assessed by the relative
ntensity of the bands, is shown in Table 4. Regarding the
nteraction with MLP, the DCM-associated mutations
howed significantly lower values (both were p  0.001),
hereas the HCM-associated mutations showed no change
p 0.78 and 0.30, respectively). As for the interaction with
itin, the DCM-associated mutations showed lower values
both were p  0.001). On the other hand, the HCM-
ssociated mutations clearly showed higher values (both
ere p  0.001). The interaction with CS-1 was at a
omparable level. The DCM-associated mutations gave
ower values (p  0.001), whereas the HCM-associated
utations gave higher values (p  0.001). Both S157A and
157D showed virtually no change in the interaction with
LP, titin, and CS-1.
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December 7, 2004:2192–201 TCAP Mutation in CardiomyopathyISCUSSION
n this study, we identified for the first time, TCAP
utations associated with HCM. The HCM-associated
utations were found in the evolutionary conserved residues
nd were absent in healthy controls. In addition, we
dentified another DCM-associated mutation. The pen-
trance of the TCAP mutations may not be high, as there
ere several unaffected blood relatives carrying the muta-
ions. In this cohort study, 2 of 236 familial HCM patients
nd 1 of 34 familial DCM patients were found to carry the
CAP mutations, suggesting that TCAP mutations may be
rare cause of cardiomyopathy.
The Z-disc of MLP knock-out mice showed widened,
ispersed, and irregular structures, and the cardiomyocytes
f MLP knock-out mice did not exhibit a hypertrophic
igure 5. The glutathion S-transferase (GST) pull-down competition assay
R87Q, E132Q, T137I, R153H, S157A, and S157D) Tcap (test-Tcap) an
t the N- and C-terminus, respectively. MLP, titin (Z1-Z2 domain), and
ST-MLP, GST-CS-1, test-Tcap, and comp-Tcap are 50, 47, 39, 35, and
nd comp-Tcap (indicated by arrows) were mixed with each GST-fusion p
nd immunoblotted with anti-GST antibody and anti-T7 antibody. (a) I
roteins in complex; (c) GST-titin protein and Tcap proteins in complex
able 4. Relative Binding of Wild-Type and Mutant Tcap to
LP, Titin, and CS-1, as Measured by the GST Pull-Down
ompetition Assays
MLP Titin CS-1
T 1.0* 1.0* 1.0*
87Q 0.22  0.04† 0.65  0.07† 0.51  0.15†
132Q 0.23  0.02† 0.53  0.10† 0.27  0.10†
137I 0.99  0.09 1.31  0.04† 1.98  0.46†
153H 0.97  0.06 1.43  0.08† 1.91  0.39†
157A 0.96  0.05 1.04  0.10 1.09  0.10
157D 0.95  0.06 0.94  0.07 0.93  0.10
Relative ratio of intensity from wild-type (WT) test Tcap to that of comp Tcap wasc
efined as 1.0. †p  0.001. Data are presented as the mean value  SD.
GST  glutathion S-transferase; other abbreviations as in Table 3.esponse to mechanical stress. On the other hand, as a
ompletely preserved Z-disc structure was observed in MLP
nd PLB (phospholamban gene) double knock-out mice, it
s presumed that the promotion of calcium cycling can
revent Z-disc defects by enhancing cardiac relaxation and
educing wall stress (20). These observations suggest an
mportant role of the Z-disc complex, titin/Tcap/MLP, in
esponse to cardiac muscle stretching. Through the Y2H
nd GST pull-down competition assays, we demonstrated
he functional alterations caused by the TCAP mutations.
ue to the impaired interaction of Tcap with MLP, titin,
nd CS-1 caused by DCM-associated mutations, mutation-
rone cardiomyocytes are more easily extended than the
ormal cardiomyocytes in the presence of mechanical
tretch. The Z-disc with mutant Tcap could affect the
tretch response and the calcium signals via CS-1 and the
alcineurin complex.
In clear contrast, due to the augmented interaction of
cap with titin and CS-1 caused by HCM-associated
utations, the Z-disc with mutant Tcap might exert an
ncreased passive tension. If the length of the muscle fiber is
onstant, the increased passive tension leads to increased
alcium sensitivity in muscle contraction (27). Therefore, it
s presumed that TCAP mutations in HCM increase cal-
ium sensitivity. The HCM-associated mutations in TPM1,
YL2, TNNT2, MYH7, and TNNI3 are reported to in-
rease calcium sensitivity (28–32), and the increased cal-
ium sensitivity may be a common fundamental change
een Tcap and the other Z-disc components. Wild-type (WT) and mutant
ort Tcap (amino acids 1–120, comp-Tcap) were fused to Thio and T7-tag
rcin-1 (CS-1) were fused to GST. The molecular weights of GST-titin,
, respectively. Equivalent amounts of test-Tcap (indicated by arrowheads)
. After incubation and washing, the complex was resolved in SDS-PAGE
mounts of test-Tcap and comp-Tcap; (b) GST-MLP protein and Tcap
(d) GST-CS-1 protein and Tcap proteins in complex.s betw
d a sh
calsa
30 kd
roteinaused by HCM-associated sarcomere mutations. It may be
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TCAP Mutation in Cardiomyopathy December 7, 2004:2192–201orth noting that Mohapatra et al. (21), by using the
mmunoprecipitation method, found a DCM-associated
LP mutation leading to decreased interaction with alpha-
ctinin, whereas Geier et al. (22), by means of an Y2H
ssay, revealed that an HCM-associated MLP mutation
ecreases the binding to alpha-actinin. It is not clear why
CM-associated and HCM-associated mutations exhib-
ted similar functional changes, but it is difficult to compare
he results because different assay systems were used in these
tudies; in particular, the Y2H assay might not be adequate
or the protein-protein interaction in mammalian cells. In
ur study, we used the pull-down assay in addition to the
2H assay in order to demonstrate the functional changes.
The Z-disc has a functional and mechanical coupling to
he T-tubule system, a site of initial Ca2-induced Ca2
elease that links excitation and contraction. Calsarcin-1
inds calcineurin, a well-known mediator of hypertrophy.
verexpression of calsarcin can inhibit calcineurin activity
19), and CS-1 interacts with Cypher/ZASP, which binds
rotein kinase C (PKC) (Fig. 1) (19,33). Of interest is that
e recently identified in a DCM family a Cypher/ZASP
utation that increases the binding to protein kinase C
33), and other Cypher/ZASP mutations were reported in
everal DCM families (34). These observations suggest that
-disc proteins may play a role in monitoring local Ca2
ignals at the Z-disc and regulating the activation of
ompensatory pathways (35). Our results suggest that the
itin/Tcap/MLP/alpha-actinin complex plays an important
ole as a stretch sensor controlling cardiac hypertrophy, as
ell as cardiac failure. The modulation of the mechanical
inks between the stretch sensor and the Ca2 signals could
ecome a therapeutic target in the future.
cope of this study. We investigated the interaction of
cap with titin, MLP, and CS-1, using two different
ethods. Because both methods are in vitro qualitative
ssays and recombinant proteins were used, the alterations
n the interaction caused by the TCAP mutations might be
ifferent in vivo. A cohort of HCM and DCM patients was
nalyzed for mutations in the known disease genes by the
SCP method, which detects a point mutation with an
fficacy of 90% or less (26). In addition, some disease genes,
uch as MYH6 (cardiac alpha-myosin heavy chain) and
YLK2 (myosin light chain kinase) for HCM and EMD
emerin) and G4.5 (tafazzin) for DCM, were not analyzed
n the patients carrying TCAP mutations. As such, the
ossibility remains that these patients might have additional
isease-related mutations.
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